IL-33/ST2 signaling can promote cell-dependent inflammatory responses and may have opposite effects in inflammatory or allergic conditions or diseases (such as cancer and autoimmune diseases) (40), reflecting the duality of action of the IL-33/ST2 pathway. This evidence concerns the gene IL1RL1 and cancer.